Intelligent Bio Solutions Launches Critical Multi-Site Study for FDA 510(k) Submission: Key Milestone Towards U.S. Market Entry
NEW YORK, June 2, 2026 – Intelligent Bio Solutions Inc. (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive drug testing, has announced a significant milestone in its path to securing U.S. regulatory clearance. The company has commenced a rigorous, multi-site Method Comparison Study, a pivotal step for its FDA 510(k) submission aimed at enabling U.S. market entry for its flagship Intelligent Fingerprinting Drug Screening System.
Key Points of the Report
- Multi-Site FDA Study Initiated: INBS has begun a formal, multi-site clinical study in partnership with CenExel Clinical Research, Inc., a prominent nationwide research site network.
- Purpose: The study is designed to validate both the accuracy and real-world performance of the Intelligent Fingerprinting Drug Screening System for the detection of codeine (an opiate) in workplace settings.
- Study Design:
- 135 donor participants, randomized into dosing groups, reflecting the demographic diversity of the U.S. population.
- Specimens collected and analyzed by nine operator participants, representing typical workplace drug screening personnel.
- Operators are not required to have specialized laboratory training, highlighting the product’s ease of use and suitability for widespread occupational deployment.
- Performance Metrics:
- Study will evaluate sensitivity, specificity, and overall accuracy of the system.
- Results independently confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS), considered the gold standard in drug detection.
- Timeline: Enrollment and data collection are expected to be completed by the end of July 2026. Study outcomes will form a key part of the FDA 510(k) submission package, alongside data from a previously announced clinical cut-off study that began in January 2026.
- Regulatory Rigor: The study adheres to International Council for Harmonisation Good Clinical Practice (ICH GCP) guidelines and U.S. national regulatory requirements.
- Market Potential: Although the technology is already sold in international markets, FDA clearance would open the lucrative U.S. market, particularly in industries such as construction, transportation, manufacturing, logistics, mining, and drug treatment organizations.
Implications for Shareholders and Potential Price Sensitivity
- Clear Regulatory Catalyst: This study represents a critical regulatory milestone. Successful completion and positive results could significantly de-risk the U.S. approval process and accelerate commercialization, which may positively impact share value.
- Ease of Use as a Competitive Advantage: The system’s ability to be operated effectively by typical workplace staff without specialized training may lower adoption barriers and expand the addressable market, enhancing growth prospects.
- Validation of Technology: Independent confirmation of accuracy and real-world usability is likely to increase confidence among regulators, customers, and investors.
- U.S. Market Entry: FDA clearance is a major potential inflection point. The U.S. workplace drug screening market is substantial, and penetration here could materially increase the company’s revenue and market capitalization.
- Forward-Looking Statements: The company notes that there are inherent risks, and actual outcomes may differ from current expectations due to regulatory, operational, or market factors.
About Intelligent Bio Solutions
Intelligent Bio Solutions Inc. delivers rapid, non-invasive testing solutions, with its Intelligent Fingerprinting Drug Screening System offering near-instantaneous detection of recent drug use, including opiates, cocaine, methamphetamine, and cannabis. With results in under ten minutes and simple, hygienic sample collection, the system is already in use in several international markets. FDA clearance would be transformative for the company’s U.S. growth ambitions.
Contact Information
- Company Contact: [email protected]
- Investor & Media Contact: Valter Pinto, Managing Director, KCSA Strategic Communications, PH: (212) 896-1254, [email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements in this article involve risks and uncertainties, and actual results may differ materially. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. Intelligent Bio Solutions Inc. undertakes no obligation to update forward-looking statements as new information becomes available.
